Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Trazodone mechanism of Action Action Pathway
Homo sapiens
Drug Action Pathway
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants with comparable efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone inhibits the reuptake of serotonin and block both histamine and alpha-1-adrenergic receptors. Other mechanisms that may occur include antagonism at serotonin 5-HT1a, 5-HT1c, and 5-HT2 receptor subtypes.
References
Trazodone mechanism of Action Pathway References
Shin JJ, Saadabadi A: Trazodone.
Pubmed: 29262060
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Sangkuhl K, Klein TE, Altman RB: Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genomics. 2009 Nov;19(11):907-9. doi: 10.1097/FPC.0b013e32833132cb.
Pubmed: 19741567
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings